Navigation Links
New Report Just Published: World Prostate Cancer Therapeutics Market Report
Date:7/7/2009

Select Prostate Cancer Drugs/Compounds in Pipeline II-14 Select Prostate Cancer Drugs Under Phase II/III Trials by Leading Companies II-15 Drugs in Pre-Clinical Stage II-16 Select Prostate Cancer Drugs/Compounds in Pre-Clinical Stage II-16 Commercially Available Drugs II-16 Select Prostate Cancer Drugs (Commercially Available) by Leading Companies II-16 3. Product Overview II-17 Cancer: A Major Health Crises in the Modern World II-17 Table 9: Mortality Rate in the US for the Year 2005 by Ailment - Heart Diseases, Cancer, Cerebrovascular Diseases, Chronic Lower Respiratory Diseases, and Accidents (Unintentional Injuries) (includes corresponding Graph/Chart) II-17 Table 10: Mortality Rate in the US for the Year 2005: Percentage Breakdown by Cause of Death -Heart Diseases, Cancer, Cerebrovascular diseases, Chronic lower respiratory diseases, Accidents (unintentional injuries), and Others (includes corresponding Graph/Chart) II-17 Table 11: Cancer Death Rates in the US (2007): Percentage Breakdown by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, Pancreas, Leukemia, and Others (includes corresponding Graph/Chart) II-18 Table 12: Comparison of Mortality Among African Americans and Whites by Cancer Type in the US, 2000- 2004 (includes corresponding Graph/Chart) II-18 Prostate - Structure II-18 Pituitary Gland II-19 Testes II-19 Prostate Cancer - A Primer II-20 Key Facts to Gaze at II-20 Table 13: Lifetime Probability of Developing Cancer (in Men) by Type in the US, 2002-2004 II-20 Table 14: New Incidences of Prostate Cancer (in '000) Worldwide for the years 2007 and 2008 (includes corresponding Graph/Chart) II-21 Table 15: Mortality Due to Prostate Cancer (in '000) Worldwide for the Years 2007 and 2008 (includes corresponding Graph/Chart) II-22
'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Mich., May 3, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... for serious central nervous system diseases, announced today that ... Trimesta™ (oral estriol) drug candidate for multiple sclerosis (MS) ... the National Institutes of Health/National Institute of Neurological Disorders ...
... Inc. (NYSE: LDR ), a recognized global ... domestic provider of outsourced medical physics services, today reported financial ...   Fiscal 2011 Second Quarter Highlights ... contribution from Medical Physics segment and international growth. Gross ...
... Verenium Corporation (NASDAQ: VRNM ), a pioneer ... today announced that Jeff Black, Senior Vice President and Chief ... Bright Lights Conference.  The presentation is scheduled to begin at ... take place at the Le Parker Meridien Hotel in New ...
Cached Biology Technology:Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 3Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12Verenium to Present at MDB Capital Group's Bright Lights Conference 2Verenium to Present at MDB Capital Group's Bright Lights Conference 3
(Date:7/9/2014)... Spanish National Cancer Research Centre (CNIO) have discovered that ... regulates cell division in stratified epitheliathose that form part ... oesophagus or the vaginain adult organisms. According to the ... Nature Communications , this factor could also play a ... epithelia of the oesophagus and skin. , The pluripotency ...
(Date:7/9/2014)... 9, 2014Biofuels derived from the oils produced by algae ... To achieve this goal, optimization of cost effective strategies ... systems, is needed. Sapphire Energy has developed an innovative ... algae cultivation systems, described in Industrial Biotechnology , ... The article is available on the Industrial Biotechnology ...
(Date:7/9/2014)... the prevalence of antibiotic-resistant illness, Case Western Reserve ... disabling disease: blocking bacteria,s access to iron in ... siderophore, a small molecule, captures iron from two ... as well as how the body launches a ... appear in a recent edition of The ...
Breaking Biology News(10 mins):CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2Controlling contamination in open algae ponds for biofuels 2Bacteria hijack plentiful iron supply source to flourish 2
... by intestinal worms a condition that affects more than ... immune system is more versatile than has long been thought. ... exploration in the search for treatments against autoimmune diseases like ... tissues. The findings, reported by scientists who performed the ...
... Forest Service Southern Research Station (SRS) scientists and partners ... faster than expected in the southern Appalachians and rapidly ... and cooperators from the University of Georgia published the ... Ecosystems . "The study marks the ...
... has found that modern lifestyle habits may play a bigger ... A review of the scientific evidence over the ... good oral hygiene and health education, may override the effects ... online in a Supplement to the journal Obesity Reviews ...
Cached Biology News:A worm-and-mouse tale: B cells deserve more respect 2A worm-and-mouse tale: B cells deserve more respect 3Study finds hemlock trees dying rapidly, affecting forest carbon cycle 2
... The mycobacteria in Complete Freund's adjuvant attract ... site which enhances the immuneresponse. For this ... for the initial injections; Incomplete Freund's adjuvant ... (preferably in saline) are typically mixed with ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
Biology Products: